Focusing the pivotal role of nanotechnology in Huntington’s disease: an insight into the recent advancements

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Environmental science and pollution research international

• Publication date

  2022-09-14

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.1007/s11356-022-22830-2PMID 36100788
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective

  2022cited by this paper
• Upcoming Meetings Related to Huntington’s Disease

  2022cited by this paper
• Application of Central Composite Design for Development and Optimization of Eflornithine Hydrochloride-loaded Sustained Release Solid Lipid Microparticles

  2021cited by this paper
• Deciphering the role of nanoparticles for management of bacterial meningitis: an update on recent studies

  2021cited by this paper
• Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

  2021cited by this paper
• Disease Onset in Huntington's Disease: When Is the Conversion?

  2021cited by this paper
• Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington’s disease

  2020cited by this paper
• Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease

  2020cited by this paper
• Solid Lipid Nanoparticles

  2020cited by this paper
• Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

  2020cited by this paper
• Targeting Huntingtin Expression in Patients with Huntington's Disease.

  2019cited by this paper
• Treating Huntington’s disease

  2019cited by this paper
• Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease.

  2019cited by this paper
• MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system.

  2019cited by this paper
• BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

  2018cited by this paper
• Huntington's disease: a clinical review

  2018cited by this paper
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

  2018cited by this paper
• Theranostic applications of nanoparticles in neurodegenerative disorders

  2018cited by this paper
• Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease

  2018cited by this paper
• SOLID LIPID NANOPARTICLES: A REVIEW

  2017cited by this paper
• Huntington’s Disease—Update on Treatments

  2017cited by this paper
• Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington's Disease Model Mouse.

  2017cited by this paper
• Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications

  2017cited by this paper
• Magnetic Nanoparticles: From Design and Synthesis to Real World Applications

  2017cited by this paper
• Compositions and methods for the treatment of neurodegenerative diseases

  2016cited by this paper
• RAN Translation in Huntington Disease.

  2015cited by this paper
• Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease

  2015cited by this paper
• Morbus Huntington

  2015influential reference
• Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

  2015cited by this paper
• Huntington disease: pathogenesis and treatment.

  2015influential reference
• Corticostriatal synaptic adaptations in Huntington’s disease

  2015cited by this paper
• Huntington disease

  2015cited by this paper
• [Huntington's disease].

  2015cited by this paper
• Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice

  2015cited by this paper
• Genetic modifiers of Huntington's disease

  2014cited by this paper
• Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk

  2014cited by this paper
• Huntington disease: natural history, biomarkers and prospects for therapeutics

  2014cited by this paper
• Curcumin Nanoparticles Attenuate Neurochemical and Neurobehavioral Deficits in Experimental Model of Huntington’s Disease

  2014cited by this paper
• Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.

  2013cited by this paper
• Nanoparticles Based Stem Cell Tracking in Regenerative Medicine

  2013cited by this paper
• Cognitive decline in prodromal Huntington Disease: implications for clinical trials

  2013cited by this paper
• Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington's disease.

  2012cited by this paper
• Preparation and characterization of solid lipid nanoparticles-a review.

  2012cited by this paper
• Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model

  2012cited by this paper
• Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications

  2012cited by this paper
• Age, CAG repeat length, and clinical progression in Huntington's disease

  2012cited by this paper
• The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysis

  2012cited by this paper
• Compositions and methods for treating neurodegenerative diseases

  2012cited by this paper
• Drug transport to brain with targeted nanoparticles

  2011cited by this paper
• Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

  2011cited by this paper
• Engaging neuroscience to advance translational research in brain barrier biology

  2011influential reference
• Huntington's disease: clinical presentation and treatment.

  2011cited by this paper
• Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.

  2010cited by this paper
• Dopamine D2 Receptor Stimulation Potentiates PolyQ-Huntingtin-Induced Mouse Striatal Neuron Dysfunctions via Rho/ROCK-II Activation

  2009cited by this paper
• Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?

  2009cited by this paper
• Nanoparticle-based targeted drug delivery.

  2009cited by this paper
• Magnetic nanoparticles for theragnostics.

  2009cited by this paper
• Molecular genetics and biomarkers of polyglutamine diseases.

  2008cited by this paper
• Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.

  2008cited by this paper
• The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?

  2008cited by this paper
• Renal clearance of quantum dots

  2007cited by this paper
• Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study.

  2007cited by this paper
• Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.

  2007cited by this paper
• Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities

  2007cited by this paper
• Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.

  2007cited by this paper
• The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test

  2007cited by this paper
• Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.

  2007cited by this paper
• Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions

  2006cited by this paper
• Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?

  2006cited by this paper
• Predictive testing for Huntington disease: interpretation and significance of intermediate alleles

  2006cited by this paper
• Huntington Disease

  2006cited by this paper
• Drug transport to brain with targeted nanoparticles

  2005cited by this paper
• Environmental Toxins and Parkinson's Disease

  2005cited by this paper
• Genetic Testing of Children for Late Onset Disease

  2005cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease.

  2004cited by this paper
• Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

  2004cited by this paper
• Cognitive and Psychiatric Aspects of Huntington Disease Contribute to Functional Capacity

  2004cited by this paper
• Transcriptional abnormalities in Huntington disease.

  2003cited by this paper
• Why is the global CNS pharmaceutical market so under-penetrated?

  2002cited by this paper
• Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.

  2002cited by this paper
• Solid lipid nanoparticles: production, characterization and applications.

  2001cited by this paper
• Juvenile onset Huntington's disease--clinical and research perspectives.

  2001cited by this paper
• Huntington's disease

  1984cited by this paper
• [The method of diagnosis].

  1960cited by this paper

• Trace Element Nanoparticles for Neurodegenerative Disease Therapy.

  2025cites this paper
• Revolutionizing healthcare: the transformative potential of nanotechnology in medicine

  2025cites this paper
• Nanotechnology-driven approaches for the management of Huntington's disease

  2025cites this paper
• MIMI-ONET: Multi-Modal image augmentation via Butterfly Optimized neural network for Huntington DiseaseDetection.

  2025cites this paper
• A REVIEW ARTICLE ON TREATING HUNTINGTON’S DISEASE: CURRENT AND EMERGING THERAPEUTIC ASPECTS

  2025cites this paper
• A clinical prognostic model of oxidative stress-related genes linked to tumor immune cell infiltration and the prognosis of ovarian cancer patients

  2024cites this paper
• Nanotechnology in the diagnostic and therapy for Alzheimer's disease.

  2024cites this paper
• Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management

  2024cites this paper
• Efficacy and safety of compound kushen injection for treating advanced colorectal cancer: A protocol for a systematic review and meta-analysis

  2024cites this paper
• Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.

  2024cites this paper
• Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics

  2023cites this paper
• Response of New Para Hydroxy Benzoic Acid Derivative and Coriandrum sativum leaves extract against periodontitis causing bacteria

  2023cites this paper
• Antibacterial Response of Cinnamomum iners Leaves Extract and Cinnamic Acid Derivative against Pathogens that Triggers Periimplantitis

  2023cites this paper